Introduction
AOD 9604 and semaglutide both feature prominently in metabolic research but operate through entirely different mechanisms and target different aspects of metabolism. AOD 9604 is a growth hormone fragment targeting adipose tissue directly, while semaglutide is a GLP-1 receptor agonist with broad metabolic effects. This comparison helps researchers select the appropriate peptide for specific metabolic investigations.
What is AOD 9604?
AOD 9604 is a modified 16-amino acid fragment of human growth hormone (residues 176-191) with a molecular weight of ~1,815 Da. It was engineered to isolate GH’s lipolytic activity without its growth-promoting or diabetogenic effects. It acts independently of the GH receptor and does not elevate IGF-1 or affect glucose metabolism.
What is Semaglutide?
Semaglutide is a 31-amino acid GLP-1 receptor agonist with a molecular weight of ~4,114 Da and a half-life of approximately 7 days. It activates GLP-1 receptors throughout the body, influencing glucose homeostasis, appetite regulation, gastric emptying, cardiovascular function, and hepatic metabolism.
Key Differences
| Feature | AOD 9604 | Semaglutide |
|---|---|---|
| Target | Adipose tissue (direct) | GLP-1 receptors (systemic) |
| Mechanism | Lipolysis stimulation, lipogenesis inhibition | GLP-1R agonism, multiple metabolic pathways |
| Effect on Glucose | Neutral | Significant (glucose-dependent insulin secretion) |
| Effect on IGF-1 | None | None (direct) |
| Appetite Effects | None documented | Significant reduction |
| Scope of Effects | Narrow (fat metabolism) | Broad (metabolic, CV, hepatic, neural) |
Research Applications Compared
Fat Metabolism Research
AOD 9604 provides a focused tool for studying adipose tissue biology — lipolysis, lipogenesis, and fat cell signaling — without confounding metabolic effects. Semaglutide affects fat mass through multiple indirect mechanisms including appetite suppression, energy balance changes, and metabolic rate modification, making it harder to isolate fat-specific mechanisms.
Glucose Homeostasis
Semaglutide is the clear choice for glucose metabolism research given its direct effects on insulin secretion, glucagon suppression, and beta-cell function. AOD 9604 has no direct effects on glucose metabolism, which can be advantageous when researchers want to study fat metabolism in isolation.
Cartilage Research
AOD 9604 has a unique research niche in osteoarthritis and cartilage repair that semaglutide does not share. This unexpected chondroprotective activity gives AOD 9604 applications beyond pure metabolic research.
Conclusion
AOD 9604 and semaglutide serve different metabolic research needs. AOD 9604 is a precise tool for studying fat metabolism in isolation, while semaglutide provides a comprehensive metabolic research compound with effects across multiple organ systems. The choice depends on whether narrow mechanistic clarity or broad metabolic modulation is required.
All products are sold strictly for research purposes only. Not for human consumption.
Related Articles
All products are sold strictly for research purposes only. Not for human consumption.